Defining and Treating High-Risk Prostate Cancer: Can We Do Better?

European Urology

Volumn 58, Issue 1, 2010, Pages 8-9

  Gerber, Leah ^a,c   Bañez, Lionel L ^a,c   Freedland, Stephen J ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; EDITORIAL; EUROPE; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; INDIVIDUALIZATION; LIFESTYLE MODIFICATION; MALE; MEDICAL DECISION MAKING; METASTASIS INHIBITION; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; PSYCHOLOGICAL WELL BEING; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77952878196     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.03.030     Document Type: Editorial

References (11)

1. Cooperberg M.R., Broering J.M., and Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28 (2010) 1117-1123
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
3. Spahn M., Joniau S., Gontero P., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58 (2010) 1-7
4. Nguyen P.L., Chen M.H., Catalona W.J., Moul J.W., Sun L., and D'Amico A.V. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 73 (2009) 659-664
5. Bastian P.J., Gonzalgo M.L., Aronson W.J., et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107 (2006) 1265-1272
6. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
7. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., and Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
8. Yossepowitch O., Eggener S.E., Serio A.M., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008) 950-959
9. Albertsen P.C. The face of high risk prostate cancer. World J Urol 26 (2008) 205-210
10. Zelefsky M.J., Eastham J.A., Cronin A.M., et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28 (2010) 1508-1513
11. Thompson I.M. Defining high risk prostate cancer-where do we set the bar? A translational science approach to risk stratification. J Urol 176 (2006) S21-S24 discussion S25-26.